Hidden fees in GLP-1 telehealth: the pricing tricks to watch for

You have probably seen the ads. A headline promises compounded semaglutide or tirzepatide for something like $199 a month, you click through, and by the time you reach checkout the number looks nothing like what was advertised. Or you sign up, the medication arrives, and three months later you realize you have been quietly enrolled in a subscription you cannot cancel without a 45-minute phone call. This is not paranoia. It is a documented pattern, and the people most likely to get caught in it are value-conscious women who have already spent years and real money on diets that did not work. You deserve a straight answer about what things actually cost before you commit to anything.

The most common pricing tricks in GLP-1 telehealth

The GLP-1 telehealth space expanded fast when compounded semaglutide and tirzepatide became widely available. Fast growth attracted legitimate providers and also a wave of companies optimized for acquisition, not patient outcomes. Knowing the specific tactics they use is the fastest way to protect yourself.

• The bait price that excludes the consult fee. A company advertises medication at a low monthly rate but bills the provider consultation separately, often as a recurring charge you did not clearly agree to.
• Tiered dose pricing with no upfront disclosure. Your starting dose is cheap. The therapeutic dose you actually need to see results costs two to three times more, and that information is buried in the FAQ rather than shown on the pricing page.
• Mandatory lab bundles. Some platforms require you to purchase an in-house lab panel before every prescription renewal, even when your own recent labs are perfectly usable. This adds $75 to $150 per cycle with no clinical justification.
• Subscription traps with no self-serve cancel. You can sign up in two clicks. Canceling requires a phone call, a chat queue, or a written request with a multi-day processing window. In the meantime, another shipment charges your card.
• Vague pharmacy sourcing. The medication is described as 'compounded' with no mention of whether the pharmacy holds a 503A or 503B designation, what state it operates in, or whether it is registered with the FDA. That vagueness is not an accident.
• Hidden shipping and cold-pack fees. Compounded GLP-1 medication ships refrigerated. Some providers quote a medication price, then add $30 to $50 for shipping at checkout as a separate line item.
• Refund policies that only apply to unopened shipments. If you have a side-effect reaction in week one and want to stop, you may find the refund window has already closed or requires return of refrigerated product at your own cost.

Why the pharmacy source question matters more than most people realize

Compounded tirzepatide is not the same thing as Zepbound or Mounjaro, which are FDA-approved finished drug products manufactured by Eli Lilly. Compounded tirzepatide is prepared by a US-licensed compounding pharmacy under a valid prescription and is not an FDA-approved finished product. That distinction matters for your safety, and the regulatory classification of the compounding pharmacy matters too.

A 503A pharmacy compounds for individual patients under a specific prescription. A 503B outsourcing facility operates under stricter federal oversight, conducts sterility testing, and can produce larger batches. Neither class is a gray market if they are properly licensed, but you should be able to find out which one your provider uses. If a company cannot or will not tell you the pharmacy name, the state it operates in, and its license class, that is a red flag. Legitimate providers treat pharmacy transparency as a baseline, not a differentiator.

The concern is not hypothetical. The FDA has flagged multiple compounding operations for quality violations related to GLP-1 products. The way you protect yourself is not by avoiding compounded medication altogether but by confirming your provider sources from a pharmacy with verifiable credentials. Ask directly. If the answer is evasive, walk away.

What transparent GLP-1 pricing actually looks like

Transparent pricing is not complicated. It just requires a provider willing to show you the full number before you enter a payment method. Here is what that looks like in practice.

• One price that covers the provider visit, the prescription, and the medication. No separate consult fee billed later.
• Dose-specific pricing shown upfront for every tier, so you know what month three costs before you commit to month one.
• Shipping and cold-pack costs included or clearly itemized on the same page as the medication price, not revealed at checkout.
• A self-serve cancel option. You should be able to stop your subscription without a phone call, a chat queue, or a waiting period.
• No mandatory in-house labs when your existing bloodwork is current and sufficient. A provider reviewing your actual health history should be able to work with labs you already have.
• A named compounding pharmacy with a disclosed license class and state of operation.
• Clear refund and pause policies written in plain language, not buried in a terms-of-service document.

None of these things are unusual to ask for. Any provider that treats these questions as unreasonable is telling you something important about how they operate.

The willpower narrative is not the issue here, but the billing structure might be

If you have spent years being told to just eat less and move more while your body resisted every effort, you already know that weight regulation is not a discipline problem. The NIH Biggest Loser study (Fothergill et al., 2016) documented that sustained caloric restriction triggers measurable metabolic adaptation, including a persistent drop in resting metabolic rate that continues even after active dieting ends. Your body was working against you at a hormonal and metabolic level, not because you lacked willpower.

GLP-1 receptor agonists like semaglutide and tirzepatide work by engaging the biology that drives hunger, satiety signaling, and the constant mental negotiation with food that patients describe as food noise. In the STEP-1 trial, participants using semaglutide lost a mean of approximately 14.9 percent of body weight over 68 weeks. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide at 15 mg produced a mean body-weight reduction of approximately 20.9 percent over 72 weeks. SURMOUNT-5 compared the two molecules head-to-head, with tirzepatide showing approximately 20.2 percent versus 13.7 percent for semaglutide. These are clinical trial figures for the tirzepatide and semaglutide molecules, not StaveMD patient data, and individual results vary. Side effects, primarily nausea, vomiting, and gastrointestinal discomfort, are real and worth discussing with a provider before you start.

The point is that the biology is real, the evidence is substantial, and you were right to suspect the problem was not your effort. What should not be real is a billing structure designed to obscure total costs until you are already committed. Separating the clinical question from the pricing question lets you evaluate both clearly. The medication can be legitimate and the pricing can still be a trap. Check both.

At StaveMD, the provider who reviews your intake is a licensed clinician, not an algorithm. Pricing is shown before you commit, pharmacy sourcing is disclosed, and you can cancel without a phone call. If you have been burned before by a telehealth company that did not operate that way, we understand why skepticism is the reasonable starting position. Receipts matter more than reassurances.